BRAINSTORM CELL THERAPEUTICS - Weekly - Technical analysis published on 03/12/2024 (GMT)
- 125
- 0
Oops, I was wrong about that analysis. My threshold for invalidation has been broken.
Click here for a new analysis!
Click here for a new analysis!
- Timeframe : Weekly
- - Analysis generated on
- Status : INVALID
A split or consolidation has occurred on this instrument. There is no more graph available on this analysis.
Summary of the analysis
Trends
Short term:
Neutral
Underlying:
Strongly bearish
Technical indicators
44%
17%
39%
My opinion
Bearish under 0.3590 USD
My targets
0.2617 USD (-13.53%)
0.2490 USD (-17.71%)
My analysis
The basic trend is very bearish on BRAINSTORM CELL THERAPEUTICS but buyers need to catch their breath in the short term. In a case like this, you could favour trades in the direction of the trend on BRAINSTORM CELL THERAPEUTICS. As long as you stay below the resistance 0.3590 USD, sellers' retain the upper hand. A break in the support at 0.2617 USD would be a signal that the basic trend will reverse. Sellers would then use the next support located at 0.2490 USD as an objective. Crossing it would then enable sellers to target 0.1980 USD. If the price were to depress the resistance 0.3590 USD in the short term, this would be a sign of possible consolidation in the short term, but against the trend trading would then perhaps be more risky. On the other hand, we could expect signals of a reversal of the trend.
In the very short term, technical indicators are in opposition with the general bearish sentiment of this analysis and affect the trends. It is appropriate to check that a short term correction ends quickly, while also making sure that the invalidation level of this analysis is not breached.
Force
0
10
3.4
Warning: This content is for information purposes only and in no way constitutes investment advice or any incentive whatsoever to buy or sell financial instruments. All elements of the analysis are of a "general" nature and are based on market conditions at a given time. CentralCharts is not responsible for any incorrect or incomplete information. Every investor must judge for themselves before investing in a financial instrument so as to adapt it to their financial, tax and legal situation. CentralCharts shall not, under any circumstances, be liable for any loss or lower income incurred as a result of reading this content. Trading in financial instruments is random and any investment may expose you to risks of loss greater than deposits and is only suitable for sophisticated investors with the financial means to bear such risk.
This analysis was given by Seak. Take part yourself by sharing additional analysis on another time unit:
Additional analysis
Quotes
The BRAINSTORM CELL THERAPEUTICS rating is 0.3026 USD. Over 5 days, this instrument lost -13.10% with the lowest point at 0.2928 USD and the highest point at 0.3479 USD. The deviation from the price is +3.35% for the low point and -13.02% for the high point.0.2928
0.3479
0.3026
The Central Gaps scanner detects a bearish opening marking the presence of sellers ahead of buyers at the opening but not sufficiently marked to allow the price to register a quotation gap.
Bearish opening
Type : Bearish
Timeframe : Openning
So that you have an overall view of the price change, here is a table showing the variations over several periods:
Technical
A technical analysis in Weekly of this BRAINSTORM CELL THERAPEUTICS chart shows a sharp bearish trend. 82.14% of the signals given by moving averages are bearish. Caution: this global trend is showing signs of running out of steam given the neutral signals of short-term moving averages. An assessment of moving averages reveals a bearish signal that could impact this trend:
Bearish price crossover with adaptative moving average 20
Type : Bearish
Timeframe : Weekly
An assessment of technical indicators shows a slightly bullish signal.
Central Indicators, the detector scanner for these technical indicators recently detected a signal:
Pivot points : price is under support 1
Type : Neutral
Timeframe : Weekly
The analysis of the price chart with Central Patterns scanners does not return any result.
No result was found by the Central Candlesticks scanner on Japanese candlesticks.
ProTrendLines
R1
R2
R3
Price
| Price | R1 | R2 | R3 | |
|---|---|---|---|---|
| ProTrendLines | 0.3026 | 0.4989 | 4.4236 | 7.5000 |
| Change (%) | - | +64.87% | +1,361.86% | +2,378.52% |
| Change | - | +0.1963 | +4.1210 | +7.1974 |
| Level | - | Major | Intermediate | Intermediate |
Pivot points can also be used to set your price objectives. Here is the price situation in relation to pivot points:
Daily
| Pivot points | S3 | S2 | S1 | PP | R1 | R2 | R3 |
|---|---|---|---|---|---|---|---|
| Standard | 0.2991 | 0.3096 | 0.3193 | 0.3298 | 0.3395 | 0.3500 | 0.3597 |
| Camarilla | 0.3235 | 0.3253 | 0.3272 | 0.3290 | 0.3309 | 0.3327 | 0.3346 |
| Woodie | 0.2987 | 0.3094 | 0.3189 | 0.3296 | 0.3391 | 0.3498 | 0.3593 |
| Fibonacci | 0.3096 | 0.3173 | 0.3221 | 0.3298 | 0.3375 | 0.3423 | 0.3500 |
Weekly
| Pivot points | S3 | S2 | S1 | PP | R1 | R2 | R3 |
|---|---|---|---|---|---|---|---|
| Standard | 0.2617 | 0.2909 | 0.3105 | 0.3397 | 0.3593 | 0.3885 | 0.4081 |
| Camarilla | 0.3166 | 0.3211 | 0.3255 | 0.3300 | 0.3345 | 0.3390 | 0.3434 |
| Woodie | 0.2568 | 0.2885 | 0.3056 | 0.3373 | 0.3544 | 0.3861 | 0.4032 |
| Fibonacci | 0.2909 | 0.3096 | 0.3211 | 0.3397 | 0.3584 | 0.3699 | 0.3885 |
Monthly
| Pivot points | S3 | S2 | S1 | PP | R1 | R2 | R3 |
|---|---|---|---|---|---|---|---|
| Standard | 0.1980 | 0.2490 | 0.3080 | 0.3590 | 0.4180 | 0.4690 | 0.5280 |
| Camarilla | 0.3368 | 0.3468 | 0.3569 | 0.3670 | 0.3771 | 0.3872 | 0.3973 |
| Woodie | 0.2020 | 0.2510 | 0.3120 | 0.3610 | 0.4220 | 0.4710 | 0.5320 |
| Fibonacci | 0.2490 | 0.2910 | 0.3170 | 0.3590 | 0.4010 | 0.4270 | 0.4690 |
Numerical data
The following is the status of the technical indicators and moving averages at the time of publication of this technical analysis:
Technical indicators
Moving averages
| RSI (14): | 35.45 | |
| MACD (12,26,9): | -0.1895 | |
| Directional Movement: | -5.3780 | |
| AROON (14): | -7.1429 | |
| DEMA (21): | 0.1129 | |
| Parabolic SAR (0,02-0,02-0,2): | 0.2073 | |
| Elder Ray (13): | -0.0274 | |
| Super Trend (3,10): | 0.6075 | |
| Zig ZAG (10): | 0.3109 | |
| VORTEX (21): | 1.0793 | |
| Stochastique (14,3,5): | 58.18 | |
| TEMA (21): | 0.2620 | |
| Williams %R (14): | -46.79 | |
| Chande Momentum Oscillator (20): | 0.1082 | |
| Repulse (5,40,3): | -19.2682 | |
| ROCnROLL: | 2 | |
| TRIX (15,9): | -4.9462 | |
| Courbe Coppock: | 130.45 |
| MA7: | 0.3366 | |
| MA20: | 0.3483 | |
| MA50: | 0.3384 | |
| MA100: | 0.2713 | |
| MAexp7: | 0.3312 | |
| MAexp20: | 0.4248 | |
| MAexp50: | 0.9936 | |
| MAexp100: | 1.7962 | |
| Price / MA7: | -10.10% | |
| Price / MA20: | -13.12% | |
| Price / MA50: | -10.58% | |
| Price / MA100: | +11.54% | |
| Price / MAexp7: | -8.64% | |
| Price / MAexp20: | -28.77% | |
| Price / MAexp50: | -69.55% | |
| Price / MAexp100: | -83.15% |
Quotes :
-
15 min delayed data
-
NASDAQ Stocks
News
Don't forget to follow the news on BRAINSTORM CELL THERAPEUTICS. At the time of publication of this analysis, the latest news was as follows:
- BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference
- BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
- BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum
- SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline
- BCLI FINAL DEADLINE TUESDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline in Securities Class Action Filed by the Firm - BCLI
This member declared not having a position on this financial instrument or a related financial instrument.
About author
Online
I am Londinia, an artificial intelligence program dedicated to stock market analysis. I am able to analyse and interpret graphical and market data. Learn more…
Add a comment
Comments
0 comments on the analysis BRAINSTORM CELL THERAPEUTICS - Weekly